Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia



Rating:

Share or cite this content

Citations should be made in the following way:
T. Karampitsakos (Patras, Greece), V. Tzilas (Athens, Greece), O. Papaioannou (Patras, Greece), E. Koukaki (Athens, Greece), M. Katsaras (Patras, Greece), E. Bouros (Athens, Greece), P. Tsiri (Patras, Greece), G. Tsirikos (Patras, Greece), E. Zarkadi (Patras, Greece), N. Ntoulias (Patras, Greece), V. Sotiropoulou (Patras, Greece), P. Efthymiou (Patras, Greece), S. Chrysikos (Athens, Greece), E. Malakounidou (Patras, Greece), F. Sampsonas (Patras, Greece), C. Kalogeropoulou (Patras, Greece), D. Bouros (Athens, Greece), A. Tzouvelekis (Patras, Greece). Safety and effectiveness of mycophenolate mofetil in interstitial lung diseases. 464

Member's Comments

No comment yet.

Related content which might interest you: Mycophenolate mofetil and azathioprine in chronic hypersensitivity pneumonitis Source: International Congress 2016 – Orphan diseases I Year: 2016 Results of switch from mycophenolate mofetil to azathioprin after lung transplantation Source: Eur Respir J 2004; 24: Suppl. 48, 178s Year: 2004 Impact of mycophenolate mofetil on lung function in chronic hypersensitivity pneumonitis and connective tissue disease related-ILD Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Use of mycophenolate mofetil for the treatment of hypersensitivity pneumonitis> Source: Virtual Congress 2020 – Natural history and management of interstitial lung diseases of known cause Year: 2020 Case series reporting the effectiveness of mycophenolate mofetil in treatment-resistant asthma Source: Eur Respir J 2013; 42: 1134-1137 Year: 2013 Mycophenolate mofetil (MMF) rescue therapy in lung transplantation: results and pharmacokinetics Source: Eur Respir J 2002; 20: Suppl. 38, 348s Year: 2002 Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. A retrospective study Source: Annual Congress 2011 - New insights in the treatment of idiopathic pulmonary fibrosis Year: 2011 Mycophenolate mofetil: an effective corticosteroid-sparing drug in steroid-dependent asthma Source: Eur Respir J 2005; 26: Suppl. 49, 49s Year: 2005 Can mycophenolate mofetil 15 mg/kg/day attenuate experimental pulmonary fibrosis in rats? Source: Annual Congress 2009 - A wide spectrum of idiopathic pulmonary fibrosis Year: 2009 Mycophenolate mofetil reduces alveolar inflammation and acute rejection and improves overall outcome after lung transplantation Source: Eur Respir J 2006; 28: Suppl. 50, 724s Year: 2006 Churg-Strauss syndrome treated with mycophenolate mofetil Source: Eur Respir J 2002; 20: Suppl. 38, 65s Year: 2002 A case series on the use of steroids and mycophenolate mofetil in idiopathic and heritable pulmonary veno-occlusive disease: is there a role for immunosuppression? Source: Eur Respir J, 57 (6) 2004354; 10.1183/13993003.04354-2020 Year: 2021 Comparison of post renal transplant tuberculosis cases receiving conventional immunosupressive therapy and mycophenolat mofetil (MMF) and/or tacrolimus (TAC) Source: Eur Respir J 2003; 22: Suppl. 45, 157s Year: 2003 Pulmonary alveolar proteinosis due to mycophenolate and cyclosporine combination therapy in a renal transplant recipient Source: Annual Congress 2012 - Respiratory manifestations of systemic disease: a holistic approach Year: 2012 Pneumocystis jiroveci Pneumonia prophylaxis in patients treated with mycophenolate mofetil for interstitial lung disease Source: Virtual Congress 2021 – Interstitial lung disease, COVID-19 and friends Year: 2021 Cyclosporine A, FK506, mycophenolate mofetil, and prednisolone differentially modulate interleukin-8 release of bronchial epithelial cells Source: Eur Respir J 2002; 20: Suppl. 38, 571s Year: 2002 The intervening effects of mycophenolate mofetil on CD34+ hematopoietic cells in bone marrow of asthma mice Source: Eur Respir J 2005; 26: Suppl. 49, 137s Year: 2005 Mycophenalate Mofetil as a corticosteroid- sparing agent in patients with sarcoidosis. Source: International Congress 2018 – Sarcoidosis, interstitial lung diseases and various clinical problems Year: 2018 Azathioprine and low-dose prednisone in chronic pulmonary sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005